Navigation Links
ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments
Date:12/4/2012

CAMBRIDGE, MA and SAN FRANCISCO, CADecember 4, 2012 The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

"We are thrilled about the potential this collaboration holds to accelerate ALS therapeutic development," said Steve Perrin, PhD, CEO and Chief Scientific Officer at ALS TDI. "Both our organizations have unique infrastructures, and by linking them this way, we may be able to advance potential treatments faster than before."

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that leads to paralysisand eventually deathdue to the loss of motor neurons in the spinal cord and brain. About 30,000 people in the United States live with the disease at any given time, and the global population of ALS patients is approximately 400,000. Approximately 5,000 new cases of ALS are diagnosed in the United States each year, and there is no known cause, cure or treatment to halt or reverse the disease. The average patient survives only two to five years following their diagnosis.

Under this new agreement, which starts immediately, Gladstone will evaluate potential pharmaceutical compounds using a human model of ALS. Gladstone generated the model by transforming skin cells from ALS patients into stem cells, known as induced pluripotent stem cells (iPS cells), and then programming them into neurons. The technique builds on a discovery for which Shinya Yamanaka, MD, PhD, a Gladstone senior investigator, won the 2012 Nobel Prize in Physiology or Medicine.

This particular iPS-based ALS model includes a gene mutation that produces TDP-43, a protein commonly found in most forms of ALS. Promising drug compounds that pass the initial evaluation process at Gladstone will be fast-tracked for pre-clinical testing a
'/>"/>

Contact: Diane Schrick
diane.schrick@gladstone.ucsf.edu
415-734-2538
Gladstone Institutes
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrigs disease
2. Gladstone scientists identify critical process in stem cell development
3. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
4. TGen leads new National Institutes of Health study of brain tumors
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Astellas and DNDi to collaborate on new drug discovery research for the treatment of NTDs
7. BGI and Aspera collaborate on high-speed data exchange to advance genome research
8. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
9. American University biologist discovers new crab species
10. Hearty organisms discovered in bitter-cold Antarctic brine
11. Microbial missing link discovered after man impales hand on tree branch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... SPRINGS, Florida , July 25, 2014 ... as more consumers are turning to digital technology for ... Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ... Inc. (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... journals need to ensure that their peer reviewers act ... to new guidelines launched by the Committee on Publication ... Reviewers set out the basic principles and standards that ... "Peer review plays an important role in ...
... power grids is challenging because fluctuating wind speed and ... varying power demand, many wind-farm managers end up wasting ... through active control including fully stopping turbines ... the power grid from spikes in supply. In a ...
... in a particular cellular pathway are linked with bladder ... early online in CANCER , a peer- reviewed ... help improve bladder cancer screening and treatment. Alterations ... is important for various cellular processes, have been implicated ...
Cached Biology News:Committee on Publication Ethics launches ethical guidelines for peer reviewers 2Genetic alterations linked with bladder cancer risk, recurrence, progression, and patient survival 2
(Date:7/25/2014)... IN (PRWEB) July 25, 2014 At ... (FAA) has granted a 60-day extension for the public ... the Special Rule for Model Aircraft established by Congress ... of 2012. The 60-day extension establishes the new deadline ... United States Department of Transportation/FAA notice published in the ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... to continue integration and expansion of PFPA,s IT ... - SRA International, Inc.,(NYSE: SRX ), a ... solutions to government organizations and commercial clients,today announced ... the Pentagon Force,Protection Agency (PFPA) Life Safety Security ...
... 11, 2008 at 9:55 a.m. EST, CHICAGO, Nov. 4 ... that O.B. Parrish, the Company,s Chief,Executive Officer, and Donna Felch, ... Annual Global Investment Conference at 9:55,a.m. Eastern Time on November ... Palace Hotel in New York City., A live audio ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... a pivotal (Phase II/III) randomized trial using ... with head and neck cancers. The decision ... the Company,s Board of Directors from the ...
Cached Biology Technology:SRA Awarded $56 Million Contract by Pentagon Force Protection Agency 2The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference 2The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference 3Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2